Successful treatment of obesity and diabetes with incretin analogue over four years in an adult with prader-willi syndrome

Practical Diabetes

Volumn 28, Issue 7, 2011, Pages 306-307

  Paisey, R B ^a   Bower, L ^a   Rosindale, S ^a   Lawrence, C ^a  

^a TORBAY HOSPITAL   (United Kingdom)

Author keywords

Incretin analogue; Prader willi syndrome; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLICLAZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; TRIACYLGLYCEROL;

ADULT; ANAMNESIS; ARTICLE; BRAIN INFARCTION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HUMAN; LABORATORY TEST; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRADER WILLI SYNDROME; SHORT STATURE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84859747673     PISSN: None     EISSN: 20472900     Source Type: Journal    
DOI: 10.1002/pdi.1621     Document Type: Article

References (13)

1. Cassidy SB, Schwartz S. In Gene Reviews [Internet]. Pagon RA, et al (eds). Seattle (WA): University of Washington, Seattle; 1993 to 6 Oct 1998 [updated Sept 2009].
2. Goldstone AP, et al. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader- Willi Syndrome female adults: Evidence for novel influences on body fat distribution. J Clin Endocrinol Metab 2001;86:4330-8. (Pubitemid 32848555)
3. Schuster DP, et al. Characterization of alterations in glucose and insulin metabolism in Prader-Willi subjects. Metabolism 1996;45:1514-20. (Pubitemid 26424580)
4. Krochik AG, et al. Characterization of alterations in carbohydrate metabolism in children with Prader-Willi syndrome. J Pediatr Endocrinol Metab 2006;19:911-8. (Pubitemid 44349746)
5. Grugni G, et al. The Italian National Survey for Prader-Willi syndrome: an epidemiologic study. Am J Med Genet 2008;146:861-72. (Pubitemid 351499790)
6. Butler JV, et al. Prevalence of, and risk factors for physical ill-health in people with Prader-Willi syndrome: a population-based study. Dev Med Child Neurol 2002;44:248-55. (Pubitemid 34406514)
7. Freeman JS. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleve Clin J Med 2009;76(Suppl):S12-9.
8. White J. Efficacy and safety of incretin based therapies: clinical trial data. J Am Pharm Assoc 2003;49(Suppl 1):S30-40.
9. Einfeld SL, et al. Mortality in Prader-Willi syndrome. Am J Ment Retard 2006;111:193-8.
10. Bizzarri C, et al. Children with Prader-Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children. Eur J Endocrinol 2010;162:499-505. Epub 17 Dec 2009.
11. Scerif M, et al. Ghrelin in obesity and endocrine diseases. Mol Cell Endocrinol 2011;340:15-25. Epub 21 Feb 2011.
12. Sze L, et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 1 Jun 2011 [Epub ahead of print].
13. Stevenson DA, et al. Deaths due to choking in Prader- Willi syndrome. Am J Med Genet 2007;143:484-7. (Pubitemid 46348920)